Commentary|Articles|June 24, 2026

ADA 2026: Diabetes Technology Innovations Expand Beyond Traditional CGM Use

Author(s)Jennifer Goldman, PharmD, RPh, CDCES, BC-ADM, FCCP

Fact checked by: Gillian McGovern, Editor, Ron Panarotti

As these tools continue to move into mainstream diabetes management, it is increasingly important that pharmacists have proficiency.

The technology presentations at the 86th American Diabetes Association (ADA) Scientific Sessions highlighted a major shift in diabetes care. Continuous glucose monitoring (CGM) is moving beyond intensive insulin management and becoming a broader therapeutic tool for people with type 2 diabetes (T2D), while automated insulin delivery systems continue to expand and emerging ketone monitoring technologies promise to improve safety and reduce the risk of diabetic ketoacidosis (DKA).